低位直肠癌全程新辅助治疗联合免疫治疗后实现临床完全缓解1例并文献复习

doi:10.3760/cma.j.cn371439-20260123-00082

摘要/Abstract

摘要：

直肠癌是常见的消化系统恶性肿瘤，其中低位直肠癌因其解剖位置的独特性，在保肛及功能保留方面面临重大挑战。目前，多项临床研究数据支持术前放化疗作为局部晚期中、低位直肠癌的标准治疗策略。现报道1例低位直肠癌患者在接受新辅助治疗联合免疫治疗后实现临床完全缓解并免除手术的治疗过程，同时回顾相关文献并进行讨论，旨在为临床诊疗提供有益的思路。

关键词: 直肠肿瘤, 肿瘤辅助疗法, 免疫疗法, 缓解诱导

温馨格, 马飞飞, 孙诚诚, 徐则宇, 崔言刚, 丛蕾. 低位直肠癌全程新辅助治疗联合免疫治疗后实现临床完全缓解1例并文献复习[J]. 国际肿瘤学杂志, 2026, 53(8): 508-512.

图/表 5

图1

图2

图3

图4

图5

参考文献 18

[1]	Scott AJ, Kennedy EB, Berlin J, et al. Management of locally advanced rectal cancer: ASCO guideline[J]. J Clin Oncol, 2024, 42(28): 3355-3375. DOI: 10.1200/jco.24.01160.
[2]	Lin ZY, Zhang P, Chi P, et al. Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy in locally advanced rectal cancer (UNION): early outcomes of a multicenter randomized phase Ⅲ trial[J]. Ann Oncol, 2024, 35(10): 882-891. DOI: 10.1016/j.annonc.2024.06.015. pmid: 38964714
[3]	Conroy T, Castan F, Etienne PL, et al. Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiotherapy in patients with locally advanced rectal cancer: long-term results of the UNICANCER-PRODIGE 23 trial[J]. Ann Oncol, 2024, 35(10): 873-881. DOI: 10.1016/j.annonc.2024.06.019. pmid: 38986769
[4]	Xia F, Wang Y, Wang H, et al. Randomized phase Ⅱ trial of immunotherapy-based total neoadjuvant therapy for proficient mismatch repair or microsatellite stable locally advanced rectal cancer (TORCH)[J]. J Clin Oncol, 2024, 42(28): 3308-3318. DOI: 10.1200/jco.23.02261.
[5]	Zhang ZF, Liu X, Chen DW, et al. Radiotherapy combined with immunotherapy: the dawn of cancer treatment[J]. Sig Transduct Target Ther, 2022, 7(1): 258. DOI: 10.1038/s41392-022-01102-y.
[6]	Yin LM, Xue JX, Li R, et al. Effect of low-dose radiation therapy on abscopal responses to hypofractionated radiation therapy and anti-PD1 in mice and patients with non-small cell lung cancer[J]. IJROBP, 2020, 108(1): 212-224. DOI: 10.1016/j.ijrobp.2020.05.002.
[7]	Tian F, Dai HH, Sha D, et al. Total neoadjuvant treatment with short-course radiotherapy followed by sintilimab plus capecitabine-oxaliplatin versus short-course radiotherapy followed by capecitabine-oxaliplatin in patients with locally advanced rectal cancer (SPRING-01): a single-centre, open-label, phase 2, randomised controlled trial[J]. Lancet Oncol, 2025, 26(8): 1043-1054. DOI: 10.1016/s1470-2045(25)00286-4. pmid: 40645192
[8]	Amatu A, Patelli G, Zampino MG, et al. Total neoadjuvant therapy followed by non-operative management or surgery in stage Ⅱ-Ⅲ rectal cancer (NO-CUT): a multicentre, single-arm, phase 2 trial[J]. Lancet Oncol, 2025, 26(12): 1612-1625. DOI: 10.1016/s1470-2045(25)00542-x.
[9]	Habr-Gama A, Perez RO, Nadalin W, et al. Operative versus non-operative treatment for stage 0 distal rectal cancer following chemo-radiation therapy[J]. Ann Surg, 2004, 240(4): 711-718. DOI: 10.1097/01.sla.0000141194.27992.32. pmid: 15383798
[10]	Pei JP, Xu HJ, Dong QS, et al. Applicability of cCR assessment criteria in pMMR rectal cancer patients treated with neoadjuvant chemoradiotherapy combined with immunotherapy[J]. Int J Surg, 2025, 111(10): 6604-6613. DOI: 10.1097/js9.0000000000002795.
[11]	中国直肠癌新辅助治疗后等待观察数据库研究协作组, 中华医学会外科学分会结直肠外科学组, 中国医师协会结直肠肿瘤医师专业委员会, 等. 直肠癌新辅助治疗后等待观察策略中国专家共识(2024版)[J]. 中华胃肠外科杂志, 2024, 27(4): 301-315.DOI: 10.3760/cma.j.cn441530-20240227-00075.
[12]	Custers PA, Beets GL, Bach SP, et al. An international expert-based consensus on the definition of a clinical near-complete response after neoadjuvant (Chemo)radiotherapy for rectal cancer[J]. Dis Colon Rectum, 2024, 67(6): 782-795. DOI: 10.1097/dcr.0000000000003209. pmid: 38701503
[13]	韩加刚, 孙丽婷, 翟志伟, 等. 多点全层穿刺活检对新辅助治疗后直肠癌缓解程度判断指导价值的前瞻性多中心研究[J]. 中华外科杂志, 2023, 61(9): 768-774. DOI: 10.3760/cma.j.cn112139-20230417-00170.
[14]	Caruso R, Vicente E, Quijano Y, et al. Role of ¹⁸F-PET-CT to predict pathological response after neoadjuvant treatment of rectal cancer[J]. Discov Oncol, 2021, 12(1): 16. DOI: 10.1007/s12672-021-00405-w.
[15]	López-López V, Abrisqueta Carrión J, Luján J, et al. Assessing tumor response to neoadjuvant chemoradiation in rectal cancer with rectoscopy and ¹⁸F-FDG PET/CT: results from a prospective series[J]. Rev Esp Enferm Dig, 2020, 113(5):307-312. DOI: 10.17235/reed.2020.6954/2020.
[16]	Tokmak H, Demir N, Çulpan HC. Total lesion glycolysis (TLG) on ¹⁸F-FDG PET/CT as a potential predictor of pathological complete response in locally advanced rectal cancer after total neoadjuvant therapy: a retrospective study[J]. Diagnostics (Basel), 2025, 15(14): 1800. DOI: 10.3390/diagnostics15141800.
[17]	Wu FP, Zhang XX, Yang CR, et al. The reduction of ¹⁸F-FDG uptake ability of tumor tissue after neoadjuvant chemoradiotherapy in locally advanced rectal cancer can effectively reflect the degree of tumor regression[J]. Front Oncol, 2022, 12: 1037783. DOI: 10.3389/fonc.2022.1037783.
[18]	Lambregts DMJ, Maas M, Boellaard TN, et al. Long-term imaging characteristics of clinical complete responders during watch-and-wait for rectal cancer—an evaluation of over 1500 MRIs[J]. Eur Radiol, 2020, 30(1): 272-280. DOI: 10.1007/s00330-019-06396-1. pmid: 31428827

低位直肠癌全程新辅助治疗联合免疫治疗后实现临床完全缓解1例并文献复习

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

图/表 5

参考文献 18

相关文章 15

编辑推荐

Metrics

本文评价

[1]	沈才路, 吴锐荣, 吴优, 葛晓松. 基于机器学习算法构建高龄结直肠癌患者术后生存预测模型[J]. 国际肿瘤学杂志, 2026, 53(8): 476-484.
[2]	刘永红, 张博, 薛玲博, 胡鹏飞, 张震宇, 李杰. XGBoost模型对乳腺癌患者新辅助化疗病理完全缓解的预测价值[J]. 国际肿瘤学杂志, 2026, 53(7): 412-419.
[3]	马池銮, 贾殿军, 魏冬冬, 王井润, 李欣萍, 赵博艳, 赵悦. 放疗同步替加氟栓联合免疫检查点抑制剂治疗老年食管癌的疗效与安全性[J]. 国际肿瘤学杂志, 2026, 53(7): 426-433.
[4]	高玉琼, 刁杰, 殷红. 溶瘤病毒在逆转肿瘤免疫治疗耐药中的研究进展[J]. 国际肿瘤学杂志, 2026, 53(7): 434-438.
[5]	李岩松, 贾军梅. 老年营养风险指数在晚期NSCLC免疫治疗预后及免疫相关不良反应中的预测价值[J]. 国际肿瘤学杂志, 2026, 53(6): 355-360.
[6]	王勇, 赵海燕, 张明明, 乌新林. 肠道微生态与结直肠癌发生发展的关系[J]. 国际肿瘤学杂志, 2026, 53(6): 370-375.
[7]	曹亚如, 刘颐, 孙鹏飞. 胃腺癌合并胃边缘区淋巴瘤伴异时性直肠腺癌1例[J]. 国际肿瘤学杂志, 2026, 53(6): 381-384.
[8]	杨松, 郑相云, 潘映雪, 王嘉明, 张焕虎. 伊马替尼辅助治疗对非胃原发高危GIST患者术后预后的影响[J]. 国际肿瘤学杂志, 2026, 53(5): 283-289.
[9]	杨心茹, 曹莉莉. CC及CXC趋化因子在肿瘤微环境中的作用及治疗潜力[J]. 国际肿瘤学杂志, 2026, 53(4): 224-228.
[10]	张奥, 崔雨. PD-1/PD-L1抑制剂在头颈部鳞状细胞癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2026, 53(4): 234-239.
[11]	仝心雨, 杨静, 王明磊, 黄承锁, 罗应舒, 彭洁琼, 韩淑梅, 刘波. 食管癌内科治疗的现状与进展[J]. 国际肿瘤学杂志, 2026, 53(4): 240-247.
[12]	李志磊, 方金满, 魏丹丹, 孙瑞霞, 张远伟. 局部晚期中低位直肠癌新辅助放化疗后病理反应的相关研究进展[J]. 国际肿瘤学杂志, 2026, 53(4): 248-252.
[13]	王雨蒙, 辛恺, 田漫漫, 邵洁, 陈文秀, 刘宝瑞, 刘芹. 个体化新抗原疫苗治疗肺腺样囊性癌1例并文献复习[J]. 国际肿瘤学杂志, 2026, 53(4): 253-256.
[14]	赵元, 姚文涛. 恶性肿瘤新辅助免疫治疗的现状与挑战[J]. 国际肿瘤学杂志, 2026, 53(1): 47-52.
[15]	王雨, 李袁飞, 郭云童. 免疫评分系统在胃癌中的研究进展[J]. 国际肿瘤学杂志, 2026, 53(1): 62-64.